Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib vs standard TKIs in advanced GIST
NCT05751733Recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Feb 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Rivoceranib in gastrointestinal stromal tumor (GIST), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Progression-Free Survival at 12 months. Started Feb 2023; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05751733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751733.